Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

Rondy, Marc; Kissling, Esther; Emborg, Hanne-Dorthe; Gherasim, Alin; Pebody, Richard; Trebbien, Ramona; Pozo, Francisco; Larrauri, Amparo; McMenamin, Jim; Valenciano, Marta; I-MOVE/I-MOVE+ group; Buda, Silke; Preuss, Ute; Prahm, Kerstin; Schweiger, Brunhilde; Wedde, Marianne; Heider, Alla; Martin, Maria; Biere, Barbara; Duerrwald, Ralf

2018-03-01Zeitschriftenartikel

Rondy, Marc

Kissling, Esther

Emborg, Hanne-Dorthe

Gherasim, Alin

Pebody, Richard

Trebbien, Ramona

Pozo, Francisco

Larrauri, Amparo

McMenamin, Jim

Valenciano, Marta

I-MOVE/I-MOVE+ group

Buda, Silke

Preuss, Ute

Prahm, Kerstin

Schweiger, Brunhilde

Wedde, Marianne

Heider, Alla

Martin, Maria

Biere, Barbara

Duerrwald, Ralf

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, −42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.

Dateien zu dieser Publikation

eurosurv-23-9-1.pdf — PDF — 543.8 Kb

MD5: 46c89bb6c7af81eb4e5957d7d0d50672

Zitieren